The prosthetic heart valve market is projected to reach USD 8.86 Billion by 2022 from USD 4.84 Billion in 2017, at a CAGR of 12.9%. Market growth can be attributed to the rising geriatric population and the subsequent increase in the prevalence of HVD, regulatory approvals for new and advanced prosthetic heart valves, increasing government funding for heart valve research, rising awareness about HVD, and favorable reimbursement scenario for prosthetic heart valves.
Years considered for this report
2016 – Base Year
2017 – Estimated Year
2022 – Projected Year
The objectives for this study are as follows:
Research Methodology
Top-down and bottom-up approaches were used to estimate and validate the size of the prosthetic heart valve market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation by type of valve and region) through percentage splits from secondary and primary research. For the calculation of each type of specific market segment, the most appropriate immediate parent market size was used for implementing the top-down approach. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. The bottom-up approach was employed to arrive at the overall size of the market from the sales of prosthetic heart valves in the respective four regions. Various secondary sources such as directories, industry journals, and databases have been used to identify and collect information useful for this extensive commercial study of the prosthetic heart valve market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the prosthetic heart valve market. The breakdown of primaries is shown in the figure below:
To know about the assumptions considered for the study, download the pdf brochure
The key players in the artificial heart valve market are Medtronic plc (Ireland), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK Healthcare Limited (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil).
Target Audience for this Report:
To Know More @ https://www.marketsandmarkets.com/Market-Reports/prosthetic-heart-valve-market-245407958.html